Everything below concerns thymosin alpha 1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Two of the most significant differences between puberty in females and puberty in males are the age at which it begins, and the major sex steroids involved, the androgens and the estrogens. Although there is a wide range of normal ages, females typically begin the process of puberty around age 10½; males at ages 11½–12. Puberty generally ends between 15–17 for females and 16–17 for males. Females attain reproductive maturity about four years after the first physical changes of puberty appear. In contrast, males accelerate more slowly but continue to grow for about six years after the first visible pubertal changes. For males, the androgen testosterone is the principal sex hormone; while testosterone is produced, all males' changes are characterized as virilization. A substantial product of testosterone metabolism in males is the estrogen estradiol. The conversion of testosterone to estradiol depends on the amount of body fat and estradiol levels in males are typically much lower than in females. The male "growth spurt" also begins later, accelerates more slowly, and lasts longer before the epiphyses fuse. Although males are on average 2 centimetres (0.8 in) shorter than females before puberty begins, adult men are on average about 13 centimetres (5.1 in) taller than women. Most of this sex difference in adult heights is attributable to a later onset of the growth spurt and a slower progression to completion, a direct result of the later rise and lower adult male levels of estradiol. The hormonal maturation of females is considerably more complicated than in males.
They organized Manchurian guerrillas against the Russians from the Chinese warlords and bandit chieftains in the region, the most important being Marshal Zhang Zuolin. The Black Dragons waged a very successful psychological warfare campaign in conjunction with the Japanese military, spreading disinformation and propaganda throughout the region. They also acted as interpreters for the Japanese army. The Kokuryūkai assisted the Japanese spy, Colonel Motojiro Akashi. Akashi, who was not directly a member of the Black Dragons, ran successful operations in China, Manchuria, Siberia and established contacts throughout the Muslim world. These contacts in Central Asia were maintained through World War II. The Black Dragons also formed close contact and even alliances with Buddhist sects throughout Asia. During the 1920s and 1930s, the Kokuryūkai evolved into more of a mainstream political organization, and publicly attacked liberal and leftist thought. Although it never had more than several dozen members at any one time during this period, the close ties of its membership to leading members of the government, military and powerful business leaders gave it a power and influence far greater than most other ultranationalist groups. In 1924, retired naval captain Yutaro Yano and his associates within the Black Dragon Society invited Oomoto leader Onisaburo Deguchi on a journey to Mongolia. Onisaburo led a group of Oomoto disciples, including Aikido founder Morihei Ueshiba.
=== Malaria === Malaria and vitamin A deficiency are both common among young children in sub-Saharan Africa. Vitamin A supplementation to children in regions where vitamin A deficiency is common has repeatedly been shown to reduce overall mortality rates, especially from measles and diarrhea. For malaria, clinical trial results are mixed, either showing that vitamin A treatment did not reduce the incidence of probable malarial fever, or else did not affect incidence, but did reduce slide-confirmed parasite density and reduced the number of fever episodes. The question was raised as to whether malaria causes vitamin A deficiency, or vitamin A deficiency contributes to the severity of malaria, or both. Researchers proposed several mechanisms by which malaria (and other infections) could contribute to vitamin A deficiency, including a fever-induced reduction in synthesis of retinal-binding protein (RBP) responsible for transporting retinol from liver to plasma and tissues, but reported finding no evidence for a transient depression or restoration of plasma RBP or retinol after a malarial infection was eliminated.
Pan, W; Tu, H; Kastin, A (2006). "Differential BBB interactions of three ingestive peptides: Obestatin, ghrelin, and adiponectin". Peptides. 27 (4): 911–6. doi:10.1016/j.peptides.2005.12.014. PMID 16476508. Steckelings, U; Kaschina, E; Unger, T (2005). "The AT2 receptor—A matter of love and hate". Peptides. 26 (8): 1401–9. doi:10.1016/j.peptides.2005.03.010. PMID 16042980. Naleid, A; Grace, M; Cummings, D; Levine, A (2005). "Ghrelin induces feeding in the mesolimbic reward pathway between the ventral tegmental area and the nucleus accumbens". Peptides. 26 (11): 2274–9. doi:10.1016/j.peptides.2005.04.025. PMID 16137788.
He therefore suggested enlarged sexual signals helped maintain the bond between a mated male and female even though they performed different duties and therefore were separated for lengths of time. A 2001 study proposed that the rounded shape of a woman's breast evolved to prevent the sucking infant offspring from suffocating while feeding at the teat; that is, because of the human infant's small jaw, which did not project from the face to reach the nipple, they might block the nostrils against the mother's breast if it were of a flatter form (compare with the common chimpanzee). Hypothetically, as the human jaw receded into the face, the woman's body compensated with round breasts. Ashley Montagu (1965) proposed that breasts came about as an adaptation for infant feeding for a different reason, as early human ancestors adopted bipedalism and the loss of body hair. Human upright stance meant infants must be carried at the hip or shoulder instead of on the back as in the apes. This gives the infant less opportunity to find the nipple or the purchase to cling on to the mother's body hair. The mobility of the nipple on a large breast in most human females gives the infant more ability to find it, grasp it and feed. Other suggestions include simply that permanent breasts attracted mates, that "pendulous" breasts gave infants something to cling to, or that permanent breasts shared the function of a camel's hump, to store fat as an energy reserve.
Sources: en.wikipedia.org
SRIs like citalopram and paroxetine, as well as the serotonin 5-HT2A receptor antagonist ketanserin, have been found to partially block the increases in heart rate and blood pressure with MDMA. It is notable in this regard that serotonergic psychedelics such as psilocybin, which act as serotonin 5-HT2A receptor agonists, likewise have sympathomimetic effects. The NRI reboxetine and the serotonin–norepinephrine reuptake inhibitor (SNRI) duloxetine block MDMA-induced increases in heart rate and blood pressure. Conversely, bupropion, a norepinephrine–dopamine reuptake inhibitor (NDRI) with only weak dopaminergic activity, reduced MDMA-induced heart rate and circulating norepinephrine increases but did not affect MDMA-induced blood pressure increases. On the other hand, the robust NDRI methylphenidate, which has sympathomimetic effects of its own, has been found to augment the cardiovascular effects and increases in circulating norepinephrine and epinephrine levels induced by MDMA. The non-selective beta blocker pindolol blocked MDMA-induced increases in heart rate but not blood pressure. The α2-adrenergic receptor agonist clonidine did not affect the cardiovascular effects of MDMA, though it reduced blood pressure. The α1-adrenergic receptor antagonists doxazosin and prazosin blocked or reduced MDMA-induced blood pressure increases but augmented MDMA-induced heart rate and cardiac output increases. The dual α1- and β-adrenergic receptor blocker carvedilol reduced MDMA-induced heart rate and blood pressure increases.
Furthermore, a study examining 20 different human tumors uncovered a recurrent mutation in ANKRD26 that adversely affects the interaction between ANKRD26 and PIDD1 with centrosomes, thereby increasing the survival of cells with more than required number of centrosomes. The process of centrosome accumulation initiates a signaling pathway characterized by the involvement of Caspase-2 and the PIDDosome, which collectively contribute to the stabilization of p53 and the induction of p21 expression. This series of events can lead to an increase in PIDD1 levels over time, as it is also a downstream target of p53. The observed rise in PIDD1 expression is likely a result of subsequent DNA damage occurring in cells that fail to effectively arrest their cell cycle in the presence of excess centrosomes. Consequently, this situation may activate p53 through either the conventional DNA damage response mechanism or as a result of delayed M-phase progression caused by complications in chromosome alignment. This mechanism guarantees the effective operation of the p21 checkpoint, which, in turn, promotes the viability of aneuploid cells. At the same time, a lack of CASP2 intensifies tumor advancement in this cancer model following treatment with cisplatin, leading to an accelerated progression of the malignancy. PIDDosome-deficient animals provide an intriguing model for exploring the effects of ploidy on liver function and regenerative processes, avoiding the complications that arise from a global deficiency of p53.
A neuron is called identified if it has properties that distinguish it from every other neuron in the same animal—properties such as location, neurotransmitter, gene expression pattern, and connectivity—and if every individual organism belonging to the same species has exactly one neuron with the same set of properties. In vertebrate nervous systems, very few neurons are "identified" in this sense. Researchers believe humans have none—but in simpler nervous systems, some or all neurons may be thus unique. In vertebrates, the best known identified neurons are the gigantic Mauthner cells of fish. Every fish has two Mauthner cells, located in the bottom part of the brainstem, one on the left side and one on the right. Each Mauthner cell has an axon that crosses over, innervating (stimulating) neurons at the same brain level and then travelling down through the spinal cord, making numerous connections as it goes. The synapses generated by a Mauthner cell are so powerful that a single action potential gives rise to a major behavioral response: within milliseconds the fish curves its body into a C-shape, then straightens, thereby propelling itself rapidly forward. Functionally of this is a fast escape response, triggered most easily by a strong sound wave or pressure wave impinging on the lateral line organ of the fish. Mauthner cells are not the only identified neurons in fish—there are about 20 more types, including pairs of "Mauthner cell analogs" in each spinal segmental nucleus.
In pharmacokinetics, a loading dose is an initial higher dose of a drug that may be given at the beginning of a course of treatment before dropping down to a lower maintenance dose. A loading dose is most useful for drugs that are eliminated from the body relatively slowly, i.e., which have a long systemic half-life. Such drugs need only a low maintenance dose in order to keep the amount of the drug in the body at the appropriate therapeutic level, but this also means that, without an initial higher dose, it would take a long time for the amount of the drug in the body to reach that level. Drugs which may be started with an initial loading dose include digoxin, teicoplanin, voriconazole, procainamide and fulvestrant. One or a series of doses may be given at the onset of therapy with the aim of achieving the target concentration rapidly.
Sources: en.wikipedia.org
==== Purity ==== One published study that analysed samples of mephedrone bought using the internet in the UK in 2010 found it was racemic (a mixture of both stereoisomers) and of high purity. An unpublished study of six samples also ordered off the internet in the UK in 2010 found they contained very few organic impurities. Four products sold in Irish head shops were tested in 2010 and were found to contain between 82% and 14% mephedrone, with some products containing benzocaine and caffeine.
Andexanet alfa is a biologic agent, a recombinant modified version of human activated factor X (FXa). Andexanet alfa differs from native FXa due to the removal of a 34 residue fragment that contains the Gla domain. This modification reduces andexanet alfa's anticoagulant potential. Additionally, a serine to alanine (S419A) mutation in the active site eliminates its activity as a prothrombin to thrombin catalyst, but still allows the molecule to bind to FXa inhibitors. FXa inhibitors bind to andexanet alfa with the same affinity as to natural FXa. As a consequence, in the presence of andexanet alfa, natural FXa is partially freed, which can lead to effective hemostasis. In other words, it acts as a decoy receptor. Andexanet alfa reverses effect of all anticoagulants that act directly through FXa or by binding antithrombin III. The drug is not effective against factor IIa inhibitor dabigatran. Its activity is measured using the anti-Xa test, which is utilized to determine the amount of available factor Xa for coagulation
Cell division is essential for an organism to grow, but, when a cell divides, it must replicate the DNA in its genome so that the two daughter cells have the same genetic information as their parent. The double-stranded structure of DNA provides a simple mechanism for DNA replication. Here, the two strands are separated and then each strand's complementary DNA sequence is recreated by an enzyme called DNA polymerase. This enzyme makes the complementary strand by finding the correct base through complementary base pairing and bonding it onto the original strand. As DNA polymerases can only extend a DNA strand in a 5′ to 3′ direction, different mechanisms are used to copy the antiparallel strands of the double helix. In this way, the base on the old strand dictates which base appears on the new strand, and the cell ends up with a perfect copy of its DNA.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.